Actively Recruiting
Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D: A Quantitative Electroencephalogram Analysis
Led by Bangladesh Medical University · Updated on 2025-07-31
15
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of vitamin D3 supplementation on brain waves in male patients with epilepsy who have low vitamin D levels. This experimental, self-controlled trial aims to compare brain electrical activity before and after vitamin D3 treatment using quantitative electroencephalogram (QEEG). The study focuses on men aged 20 to 40 years who have a diagnosis of epilepsy and hypovitaminosis D, with the goal of understanding whether vitamin D3 can improve brain wave patterns in this population. Participants will take vitamin D3 capsules orally at a dose of 50,000 IU once a week for 8 weeks. At the start of the study, baseline QEEG and serum vitamin D levels will be recorded. After the 8-week supplementation period, these measurements will be repeated to assess changes. The study uses specific EEG equipment and software to analyze the alpha, beta, theta, and delta brainwave activity. During the trial, participants will visit the medical university for baseline and post-treatment evaluations, including blood tests and QEEG recordings. They are asked to bring empty vitamin D supplement packaging to monitor adherence. The primary outcome measures the effect of vitamin D3 on brain waves over the 8-week period. Safety and health status will be monitored, and statistical methods will be applied to compare pre- and post-supplementation results.
CONDITIONS
Brief Title
Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed male patients with epilepsy by neurologist with at least two unprovoked or reflex seizures more than 24 hours apart
- Hypovitaminosis D (vitamin D level less than 30 ng/ml)
- Body Mass Index (BMI) between 20 and 24 kg/m8
- On enzyme-inducing antiepileptic drugs (e.g., Carbamazepine, Phenytoin, Phenobarbital) for 6 months to 2 years
- Not taking other central nervous system medications besides antiepileptic drugs
- Apparently normal physical health
You will not qualify if you...
- Patients suffering from absence seizures
- Taking certain antiepileptic drugs such as Sodium valproate, Ethosuximide, Oxcarbazepine, Topiramate, Lamotrigine, Levetiracetam
- Smokers
- Alcoholics
- Known hypersensitivity to vitamin D3
- Patients with hypertension
- Patients with thyroid disorders
- Patients with diabetes mellitus
- Patients with renal disease
- Patients with liver disease
- Patients with hypercalcemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants take vitamin D3 capsules orally at a dose of 50,000 IU once per week for 8 weeks.
Weekly visits for 8 weeks
Duration - 1 week
After completing vitamin D3 supplementation, participants have serum vitamin D levels measured and brain wave activity recorded using quantitative electroencephalogram (QEEG).
1 visit (in-person) after treatment completion
Trial Site Locations
Total: 1 location
1
Bangladesh Medical University
Dhaka, Shahbag, Dhaka, Bangladesh, 1000
Actively Recruiting
Research Team
R
Registrar, BMU
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here